Case presentation
59 year old gentleman with background of Diabetes and hypertension was
diagnosed as a case of chronic myeloid leukemia in the month of April
2018.He was initially started on hydroxyurea for cytoreduction that he
received for 2 weeks, afterwards switched to second generation tyrosine
kinase inhibitor Dasatinib 100mg/d for 4 weeks. It was terminated
because of severe diarrhea. He was then started on Nilotinib, that was
also poorly tolerated because of worsening of his diabetes and
persistent nausea. Bosutinib, was introduced in june 2018 and was
continued till date. Not only he tolerated it well but also showed an
exceptionally good, above average response MMR within 4 months. He
didn’t suffer from common side effects related to bosutinib such as
Diarrhea, pleural effusion or Qtc prolongation.